secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001493152-24-039016
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell: 100% resolution of temporal lobe brain metastasis in heavily pre-treated breast cancer patient
--------------------------------------------------------------------------------

- Patient with 'eye-bulging' orbital tumor and brain metastasis achieved complete resolution of temporal lobe lesion at 8 and 11 months on Bria-IMT plus checkpoint inhibitor.
- Heavily pre-treated patient had failed 8 prior regimens including ADC therapy; continues treatment after 17 cycles and 12 months on study.
- Orbital tumor showed near-complete resolution; tumor markers (blood tests) sustained drop confirming imaging results.
- CEO cites unprecedented potential in metastatic breast cancer brain metastasis; Phase 3 study evaluating brain metastasis subgroup ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224039016/0001493152-24-039016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224039016/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-039016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer